Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Taube, A. Klein, J. Brahmer, Haiying Xu, Xiaoyu Pan, J. Kim, Lieping Chen, D. Pardoll, S. Topalian, R. Anders (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 TherapyClinical Cancer Research, 20
P. Tumeh, C. Harview, J. Yearley, I. Shintaku, E. Taylor, L. Robert, B. Chmielowski, M. Spasić, G. Henry, V. Ciobanu, Alisha West, M. Carmona, C. Kivork, E. Seja, Grace Cherry, Antonio Gutierrez, T. Grogan, C. Mateus, G. Tomasic, J. Glaspy, R. Emerson, H. Robins, R. Pierce, D. Elashoff, C. Robert, A. Ribas (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 515
Dennie Frederick, A. Piris, Alexandria Cogdill, Z. Cooper, C. Lezcano, Cristina Ferrone, D. Mitra, Andrea Boni, Lindsay Newton, Chengwen Liu, W. Peng, R. Sullivan, D. Lawrence, F. Hodi, W. Overwijk, G. Lizée, G. Murphy, P. Hwu, K. Flaherty, D. Fisher, J. Wargo (2013)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic MelanomaClinical Cancer Research, 19
Douglas Johnson, M. Estrada, R. Salgado, V. Sanchez, D. Doxie, S. Opalenik, A. Vilgelm, Emily Feld, Adam Johnson, A. Greenplate, M. Sanders, C. Lovly, Dennie Frederick, M. Kelley, A. Richmond, J. Irish, Y. Shyr, R. Sullivan, I. Puzanov, J. Sosman, J. Balko (2016)
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapyNature Communications, 7
C. Hua, L. Boussemart, C. Mateus, É. Routier, C. Boutros, H. Cazenave, R. Viollet, Marina Thomas, Séverine Roy, N. Benannoune, G. Tomasic, J. Soria, S. Champiat, M. Texier, E. Lanoy, C. Robert (2016)
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.JAMA dermatology, 152 1
B. Sapkota, C. Hill, B. Pollack (2013)
Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cellsOncoimmunology, 2
This case report describes a patient with advanced melanoma initially resistant to nivolumab therapy, treated with vemurafenib, and then rechallenged with nivolumab after development of vemurafenib-related adverse effects.
JAMA Dermatology – American Medical Association
Published: May 28, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.